bioRxivCancer Biology
Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis
J. Funk, M. Klimovich, E. Pavlakis, M. Neumann, D. Drangenstein, M. Noeparast, P. Hunold, A. Borowek, D.-I. Balourdas, K. Kochan, N. Merle, I. Bullwinkel, M. Wanzel, S. Elmshauser, A. Nist, T. Procida, M. Bartkuhn, K. Humpert, M. Mernberger, R. Savai, A. C. Joerger, T. Stiewe
Abstract
The tumor suppressor gene TP53 is the most frequently mutated gene in various cancers. Unlike other tumor suppressors, TP53 is mostly hit by missense mutations, of which more than 2,000 have been described in cancer patients. To take advantage of TP53 mutation status for personalized therapy, a deeper knowledge of the functional ramifications of specific mutations is required as evidence of the functional heterogeneity of mutant p53 proteins mounts. Here, we report on a CRISPR-based saturation mutagenesis screen of 9,225 variants expressed from the endogenous TP53 gene locus of a cancer cell. By tracking changes in the abundance of individual variants in response to specific p53-pathway stimulation, we were able to construct high-resolution functional activity maps of the TP53 mutome, covering [~]94.5% of all cancer-associated missense mutations. The results demonstrate the impact of individual mutations on tumor cell fitness with unprecedented precision and coverage, even revealing underlying mechanisms such as apoptosis. The high discriminatory power also resolves subtle loss-of-function phenotypes and highlights a subset of mutants as particularly promising targets for pharmacological reactivation. Moreover, the data offer intriguing insight into the role of aberrant splicing and nonsense-mediated mRNA decay in clearing truncated proteins due to not only nonsense, frameshift, and splice-site mutations but also missense and synonymous mutations. Surprisingly, no missense mutation provided an immediate proliferative advantage over a null mutation. Nonetheless, cells with a missense, but not null mutations, acquired pro-metastatic properties after prolonged growth in mice, emphasizing the significance of mutant p53-directed clonal evolution in the progression of tumors towards metastasis.
- organism: human
- research focus: cell type annotation
- research focus: clustering
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of mutant TP53 does not impair the sustained proliferation, survival ormetastasis of diverse cancer cells
Z. Wang, F. Vailllant, … A. Strasser·bioRxiv·Mar 30, 2020
- Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers
L. Malhotra, A. Singh, … A. S. Ethayathulla·bioRxiv·Feb 6, 2023
- Mutational Landscape of TP53 Across Cancer Types
Maria Abran·bioRxiv·Aug 12, 2025
- In-Silico Characterization of TP53 Splice Mutations in Somatic and Germline Tumours
Apeksha Arun Bhandarkar, Noah Ethan Kelly-Foleni, … Sunali Y. Mehta·International Journal of Molecular SciencesPeer-reviewed·Dec 16, 2025
- Mis-splicing Drives Loss of Function of p53E224D Point Mutation
Ian C. Lock, Nathan H. Leisenring, … David G. Kirsch·PLoS ONEPeer-reviewed·Mar 5, 2025
- Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors
Charlotte Strandgren, Veronica Rondahl, … Klas G. Wiman·Cell Death and DiseasePeer-reviewed·Dec 11, 2025